Vivax malaria resistant to treatment and prophylaxis with chloroquine

Murphy, Gerald S.; Basri, Hasan; Andersen, Ellen M.; Bangs, Michael J.; Gorden, Jed A.; Sorensen, K; Mount, Dwight L.; Lal, Altaf A.; Purwokusumo, A.R.; Harjosuwarno, S; Hoffman, Stephen L.

doi:10.1016/0140-6736(93)92568-e

Cited by 187 publications

(99 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When a similar study was conducted with nonimmune Indonesian adults, no influence was observed on the incidence of falciparum or vivax malaria (49). Interestingly, the parasites circulating in the study area proved to be highly CQ resistant (50,51). When interpreted in the light of our results, these observations suggest another nefarious consequence to the spread of CQ resistance.…”

Section: Discussionmentioning

confidence: 56%

Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment

Belnoue

Costa

Frankenberg

et al. 2004

The Journal of Immunology

210

281

View full text Add to dashboard Cite

In this study we present the first systematic analysis of the immunity induced by normal Plasmodium yoelii sporozoites in mice. Immunization with sporozoites, which was conducted under chloroquine treatment to minimize the influence of blood stage parasites, induced a strong protection against a subsequent sporozoite and, to a lesser extent, against infected RBC challenges. The protection induced by this immunization protocol proved to be very effective. Induction of this protective immunity depended on the presence of liver stage parasites, as primaquine treatment concurrent with sporozoite immunization abrogated protection. Protection was not found to be mediated by the Abs elicited against pre-erythrocytic and blood stage parasites, as demonstrated by inhibition assays of sporozoite penetration or development in vitro and in vivo assays of sporozoite infectivity or blood stage parasite development. CD4+ and CD8+ T cells were, however, responsible for the protection through the induction of IFN-γ and NO.

show abstract

Section: Discussionmentioning

confidence: 56%

Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment

Belnoue

Costa

Frankenberg

et al. 2004

The Journal of Immunology

210

281

View full text Add to dashboard Cite

show abstract

“…1 In Indonesia, chloroquine is the recommended drug of first choice for treating malaria 2 despite its poor efficacy against falciparum malaria [2][3][4][5] and the recent emergence of chloroquineresistant Plasmodium vivax. 3,[5][6][7][8] Using combination treatment of currently available drugs is a rational approach to combating drug resistance and avoids the long wait for antimalarial drugs in development. 9 Drugs with different mechanisms of action may enhance their respective efficacies and extend their therapeutic ''life spans,'' a major public health consideration for developing countries whose need for effective drugs is pressing.…”

Section: Introductionmentioning

confidence: 99%

Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia.

Taylor¹,

Widjaja²,

Richie³

et al. 2001

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Combination therapy is one method of overcoming the global challenge of drug-resistant Plasmodium falciparum malaria. We conducted a hospital-based 28-day in vivo test comparing chloroquine/doxycycline to chloroquine or doxycycline alone for treating P. falciparum and Plasmodium vivax malaria in Irian Jaya, Indonesia. Eighty-nine patients with uncomplicated falciparum malaria were randomized to standard dose chloroquine (n ϭ 30), doxycycline (100 mg every 12 hours [7 days], n ϭ 20), or chloroquine with doxycycline (n ϭ 39); corresponding numbers for vivax malaria (n ϭ 63) were 23, 16, 24. Endpoints were parasite sensitivity (S) or resistance (RI/RII/ RIII Chloroquine/doxycycline was effective against P. falciparum but only modestly effective against P. vivax. These findings support the use of chloroquine/doxycycline as an inexpensive alternative to mefloquine for treating chloroquine-resistant P. falciparum but not chloroquine-resistant P. vivax in this setting.

show abstract

“…The first report of clinical resistance came from Papua New Guinea in 1989 1 followed by successive reports of chloroquine-resistant vivax malaria from Irian Jaya, [2][3][4][5] Myanmar, 6,7 India, 8 Sumatra, 9 and Sulawesi. 10 In the New World, chloroquine-resistant Plasmodium vivax has been described in Guyana.…”

mentioning

confidence: 99%

Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.

Fryauff¹,

Tuti²,

Mardi³

et al. 1998

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Vivax malaria resistant to treatment and prophylaxis with chloroquine

Cited by 187 publications

References 21 publications

Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment

Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment

Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia.

Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.

Contact Info

Product

Resources

About